Effectiveness of Intratympanic Dexamethasone With Ligmocaine for Alleviation of Tinnitus

Effectiveness of Dexamethasone With Lignocaine for Alleviation of Tinnitus

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04798391

Enrollment

264

Registered

2021-03-15

Start date

2021-03-01

Completion date

2021-05-31

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Brief summary

Objective: To determine the effectiveness of Intratympanic dexamethasone with lignocaine in control of idiopathic tinnitus. Methodology: 264 consenting patients with idiopathic unilateral tinnitus presenting at ENT Department were assessed for tinnitus severity using Modified Tinnitus Handicap Inventory and the scores recorded and subsequently administered intratympanically 2.0 ml (milliliter's) of dexamethasone and lignocaine (1.5 ml dexamethasone + 0.5 ml 1% lignocaine). The dose was repeated twice at weekly intervals. All patients were re assessed on Modified Tinnitus Handicap Inventory two weeks after third Intratympanic administration.

Interventions

DRUGDexamethasone

Steroids and analgesics

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 75 Years

Healthy volunteers

Inclusion criteria

* score 20 or above on modified tinnitus handicap inventory

Exclusion criteria

* head trauma, tympanic membrane perforation, depression, ear surgery

Design outcomes

Primary

Measure	Time frame	Description
Tinnitus relief	2 weeks	Tinnitus relief ascertained by Modified Tinnitus Handicap Inventory

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026